A major study published today in The BMJ found that GLP-1 receptor agonists, the class of drugs that includes semaglutide, reduced the risk of developing cannabis use disorder by 14% and cut drug-related deaths by 50% in people already living with addiction. The study covered 606,434 U.S. veterans and points toward a shared craving pathway that GLP-1 medications may be quietly rewriting.
Table of Contents
GLP-1 Drugs Reduce Cannabis Use Disorder Risk, BMJ Study Shows
A landmark cohort study of more than 600,000 American veterans, published today in The BMJ, found that popular GLP-1 medications including semaglutide were linked to a 14% lower risk of cannabis use disorder, a 25% lower risk of opioid use disorder, and a 50% reduction in drug-related deaths. The researchers suggest these drugs may be doing something far more fundamental than managing blood sugar or body weight: they may be quieting the biology of craving itself.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →Published in one of medicine’s most respected journals, this study directly intersects two areas at the center of CED Clinic’s clinical work: the endocannabinoid system and metabolic medicine. For patients using or considering GLP-1 therapies, and for those managing cannabis use alongside other health conditions, the implications are immediate and clinically meaningful.
- What the BMJ study found about GLP-1 drugs and cannabis use disorder risk, broken down by substance
- Why GLP-1 receptor agonists may reduce cravings across all addictive substances, not just one
- How the endocannabinoid system and GLP-1 pathway interact in the brain’s reward circuitry
- What these findings mean for patients navigating both metabolic conditions and cannabis medicine
- Why an observational study of this size still demands a careful, calibrated reading
- GLP-1 drugs like semaglutide were linked to a 14% lower chance of developing cannabis use disorder among 524,817 veterans with diabetes but no prior addiction
- Among 81,617 veterans who already had a substance use disorder, GLP-1 users saw 40% fewer overdoses and 50% fewer drug-related deaths over three years
- Researchers believe GLP-1 medications may work by dampening the craving signal itself, not by targeting any specific drug or substance
- This was an observational cohort study, not a randomized controlled trial; association is not proof of causation and clinical trials are still needed
| Study Type | Large-scale retrospective cohort study using electronic health records |
| Participants | 606,434 U.S. veterans with type 2 diabetes; 524,817 without SUD, 81,617 with existing SUD |
| Intervention | GLP-1 receptor agonists (primarily semaglutide, liraglutide, dulaglutide) vs. SGLT2 inhibitors |
| Follow-up | Up to 3 years of health record review after medication initiation |
| Key Finding (Prevention) | 14% lower risk of any SUD; cannabis 14%, opioids 25%, cocaine 20%, nicotine 20%, alcohol 18% |
| Key Finding (Existing SUD) | 40% reduction in overdoses; 50% reduction in drug-related deaths; 30% fewer ED visits |
| Journal | The BMJ, 2026;392:e086886 — PMID 41781010 |
| Institution | Washington University School of Medicine in St. Louis / VA Saint Louis Health Care System |
| Funding | U.S. Department of Veterans Affairs; authors declared no competing interests with the findings |
| Limitation | Observational design; predominately male, older veteran population; confounding possible despite active-comparator design |
Substance use disorders represent one of the most persistent failures of modern medicine. We have partial answers for alcohol. We have partial answers for opioids. For cocaine and methamphetamine, we have almost nothing in the pharmacological toolkit. A single class of medication that may reduce risk and severity across all of them simultaneously would be, in the truest sense of the word, a different kind of medicine.
For cannabis clinicians specifically, this study opens a conversation that has been quietly building for years. Patients who use GLP-1 drugs for metabolic conditions are increasingly asking whether their cannabis use will be affected. Patients in cannabis treatment for conditions like PTSD, chronic pain, or sleep disorders often have comorbid metabolic dysfunction. The two streams of medicine, long treated as separate domains, now share a data set of 600,000 people and a question worth taking seriously.
What the Study Found and How It Was Designed
Researchers at Washington University and the VA Saint Louis Health Care System examined electronic health records from 606,434 American veterans with type 2 diabetes. They divided participants into two groups: those who had no substance use disorder at baseline (524,817 people), and those who already carried a diagnosis (81,617 people). They then compared outcomes between veterans who were prescribed GLP-1 receptor agonists, primarily semaglutide, liraglutide, and dulaglutide, against veterans on SGLT2 inhibitors, another class of diabetes medication. The active-comparator design was a deliberate choice: it reduces the chance that healthier, less addicted patients simply gravitate toward GLP-1 medications, which would inflate the apparent benefit.
Among those without a prior diagnosis, GLP-1 use was associated with a 14% lower chance of developing any substance use disorder over the study period. The risk reduction held across every category tested: 18% lower for alcohol, 14% lower for cannabis, 20% lower for cocaine, 20% lower for nicotine, and 25% lower for opioids. The researchers calculated that this translated to approximately seven fewer new substance use disorder diagnoses for every 1,000 GLP-1 users.
The picture in the group that already had substance use disorders was more striking still. Over three years, GLP-1 users in this group experienced 30% fewer emergency department visits, 25% fewer hospitalizations, 40% fewer overdoses, and 50% fewer drug-related deaths. Twelve fewer serious addiction-related events per 1,000 users. These are large signals by epidemiological standards.
The Biology Behind the Numbers
The theoretical mechanism is not new, though the population evidence is. GLP-1 receptors are present not only in the pancreas and gut but also in brain regions that govern reward, reinforcement, and craving, including the nucleus accumbens, ventral tegmental area, and prefrontal cortex. These are the same circuits that drive drug-seeking behavior regardless of the substance. The hypothesis, long supported by preclinical work, is that GLP-1 agonism may dampen dopaminergic responses to rewarding stimuli, reducing the motivational pull toward any pleasurable substance rather than targeting one specific drug’s receptor. Lead author Ziyad Al-Aly, MD, described it as quieting “drug noise,” a phrase that will resonate with any clinician who has worked with patients on semaglutide reporting reduced interest in alcohol, cigarettes, or other compulsive behaviors alongside their food intake changes.
This study does not prove that GLP-1 drugs cause reductions in substance use disorder. Observational research, even large and well-designed observational research, identifies associations rather than causal relationships. There could be unmeasured differences between patients who received GLP-1 drugs and those who received SGLT2 inhibitors, differences in prescribing patterns, patient motivation, clinical context, or concurrent care that contributed to the findings.
The study population was predominantly older male veterans, which limits generalizability to women, younger adults, and people without military health insurance. Veterans also receive care within a coordinated system that may not reflect the fragmented experience of most patients seeking addiction or metabolic treatment in private or community settings.
The paper does not address dose, duration, which GLP-1 formulation drove the strongest signals, or how effects might differ across different patterns of substance use. Cannabis use disorder diagnoses in electronic health records are also notoriously undercoded, which could affect the precision of the cannabis-specific findings. The authors acknowledge that randomized controlled trials are the necessary next step.
How This Fits With the Broader Clinical Conversation
This study did not arrive in isolation. In 2024, a retrospective cohort study found that semaglutide was associated with reduced incidence and relapse of cannabis use disorder specifically in real-world populations. Earlier work documented GLP-1 agonists lowering alcohol consumption in animal models and reducing alcohol-related hospitalizations in humans. The 2026 WashU BMJ paper is the largest and most comprehensive synthesis of these signals across all major substance classes in a single human dataset.
The endocannabinoid system connection is particularly relevant for CED Clinic patients. The ECS and the GLP-1 pathway are not separate biological actors. Both modulate dopaminergic reward circuits. Both influence appetite and metabolic signaling. Research from 2025 documented molecular crossover between GLP-1 receptors and endocannabinoid pathways in key brain regions. Patients who use cannabis medicinally and also take GLP-1 drugs for metabolic management are navigating a biologically active intersection that clinical medicine has barely begun to map.
What this means in practice is not yet prescriptive. Physicians cannot currently recommend GLP-1 drugs for cannabis use disorder off-label with confidence, because the RCT evidence does not yet exist. But they can have more informed conversations about what is biologically plausible, what the early signals suggest, and how to monitor patients who happen to be taking both classes of agent.
For more on the intersection of these systems, see CED Clinic’s review of endocannabinoid system and GLP-1 receptor research.
This paper stops me in my tracks, not because the finding is shocking to anyone who watches biology closely, but because of its scale. Six hundred thousand people is not a pilot signal. It is a population message, and that message is that something fundamental about craving may be addressable in a way that doesn’t depend on which substance a patient is reaching for.
In my clinic, I see this intersection constantly, and I am not talking about a small niche. Patients with obesity or type 2 diabetes who are also managing anxiety, PTSD, or chronic pain with cannabis are not unusual. They are common. Patients who struggled with alcohol or opioids before finding that cannabis helped them taper or abstain are common. The question of how a GLP-1 drug interacts with the endocannabinoid system in a person who uses cannabis medicinally is not academic for me. It is Tuesday morning clinic.
The concept of “drug noise” that Al-Aly describes maps precisely onto what many of my patients describe about their cannabis use: that it quiets something. An irritability. A preoccupation. A craving that was previously pulling them toward substances that were far more harmful. Cannabis itself, when used thoughtfully for specific indications, may be doing a version of what these researchers are describing at the GLP-1 receptor level. The question of whether these two systems are additive, complementary, or occasionally antagonistic is one of the most interesting clinical questions I can think of right now.
I want to be honest about what we do not know. This is observational data. The veteran population is specific. The findings for cannabis use disorder are real but should be understood in the context of an active-comparator design that still cannot fully account for confounding. The numbers are promising, not conclusive. A clinician who tells a patient that semaglutide will treat their cannabis use disorder is getting well ahead of the evidence.
What I take from this study is permission to have a richer, more biologically grounded conversation with my patients. When someone using cannabis for PTSD asks whether their GLP-1 medication will change their experience, I now have actual data to discuss. When a patient with cannabis use disorder asks whether there is a pharmacological option on the horizon, I can say that something meaningful is being investigated and the early signals are real.
The addiction medicine field has been searching for a cross-substance treatment for decades. This paper does not deliver one. But it points in a direction that deserves rigorous, urgently designed randomized trials. Until those trials exist, the practical takeaway is watchful, curious, clinically engaged care. That, in cannabis medicine, is the only kind of care that has ever served our patients well.
What a Careful Reader Should Take Away
The headline number, a 14% reduction in cannabis use disorder risk, is real but should be understood within its methodological container. This is an association, not a causation. The study was not designed to test GLP-1 drugs as addiction treatments. The researchers were looking at existing health records for people prescribed these drugs for diabetes and metabolic disease. That the addiction signal emerged at all, and that it emerged uniformly across every substance category, is what makes this scientifically interesting.
The 50% reduction in drug-related deaths among those with existing substance use disorders is the number that deserves the most serious attention. Even in an observational design, a signal that size in a population that large, against an active comparator, is hard to dismiss. It warrants prioritized randomized trial investment.
For patients taking GLP-1 medications: do not use this study to self-modify your cannabis or substance use plan without talking to your physician. For patients managing cannabis use disorder: this study suggests promising pharmacological avenues are under active investigation. For clinicians: take the biology of GLP-1 receptor action in reward circuits seriously when discussing both metabolic and addiction-adjacent treatment plans. The systems are not separate.
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway
If you are taking a GLP-1 medication like Ozempic, Wegovy, or Mounjaro for diabetes or weight management, this study suggests you may also have a lower chance of developing a substance use problem, including cannabis use disorder. That is an interesting signal, and one that patients deserve to know about. But it does not mean the drug is treating your addiction, and it certainly does not mean you should adjust how you use cannabis or any other substance based on this finding alone.
The people in this study were veterans being treated for type 2 diabetes. The GLP-1 drug was prescribed for metabolic reasons. The addiction-related finding emerged afterward, as researchers looked back through health records. That backstory matters because it means we do not yet know what dose or duration would be relevant, or whether the benefit holds in people without diabetes, or in younger women, or in people who use cannabis for medical purposes with no history of problematic use.
What this paper legitimately tells a patient is that there may be meaningful overlap between the body systems that GLP-1 drugs affect and the body systems involved in craving. That is worth discussing openly with your physician, especially if you are managing both a metabolic condition and a complicated relationship with any substance.
Clinician’s POV
The active-comparator design here, GLP-1 agonists versus SGLT2 inhibitors rather than versus placebo or no treatment, is a meaningful methodological choice that reduces confounding by indication. Patients who receive GLP-1 drugs are not simply healthier than those who receive nothing. The question becomes whether they are systematically different from SGLT2 users in ways that explain the addiction findings, and while that possibility cannot be ruled out, the finding’s consistency across all substance categories is a noteworthy feature. Selective bias would more plausibly produce a stronger signal in one or two substance categories, not uniformly across six.
In the exam room, I would not counsel a patient that their GLP-1 prescription is reducing their cannabis use disorder risk. The evidence does not support that level of specificity. What I would note is that if a patient using cannabis medicinally is also managing obesity or diabetes, the overlap in receptor biology is real, and monitoring for changes in cannabis tolerance, frequency of use, or motivation to use is clinically appropriate. If a patient with cannabis use disorder is being considered for GLP-1 therapy for metabolic reasons, this study gives some basis for monitoring addiction-related outcomes alongside metabolic markers. That is a meaningful addition to an already data-rich medication category.
A Skeptical Read
The study population is 606,434 U.S. veterans receiving care through the VA system. Veterans are overwhelmingly male, predominantly older, and receive care within an integrated health system that is structurally different from most Americans’ medical experience. The VA prioritizes continuity of care, medication adherence, and longitudinal monitoring in ways that community clinics often cannot replicate. A 14% risk reduction in cannabis use disorder observed in this population may not survive translation to a general outpatient clinic serving younger, more diverse patients with less care continuity.
A skeptical reader also notes that cannabis use disorder is among the most underdiagnosed conditions in electronic health records. Patients rarely self-report problematic cannabis use to their primary care physician, and clinicians rarely code for it. If the electronic health record undercounts cannabis use disorder diagnoses systematically, the 14% signal may be measuring documentation rates as much as clinical outcomes. The 50% reduction in drug-related deaths deserves less skepticism on these grounds because death is a harder endpoint to miss, but the substance-specific percentages should be held with appropriate methodological humility.
Study Critic
The core limitation here is the one this type of study cannot escape: unmeasured confounding. Even with an active comparator, patients and clinicians choose GLP-1 drugs over SGLT2 inhibitors for reasons that are not fully captured in electronic health records. Prescribing preferences, insurance patterns, clinical culture at individual VA facilities, patient willingness to self-inject versus take an oral medication, concurrent behavioral support, and unmeasured psychiatric comorbidities could all influence both the likelihood of receiving a GLP-1 drug and the likelihood of developing or escalating substance use. The paper does not claim to have fully controlled for these factors, and no observational design can.
The relative risk reductions sound large, 14% lower cannabis use disorder risk, 50% fewer drug-related deaths, but the absolute numbers matter too. Seven fewer SUD diagnoses per 1,000 GLP-1 users means 993 out of 1,000 had the same outcome regardless. Twelve fewer serious events per 1,000 existing-SUD users is clinically meaningful in population terms but modest at the individual patient level. The study was not powered or designed to evaluate dose-response, to compare individual GLP-1 agents head-to-head, or to isolate which patient characteristics predicted the strongest benefit. Those analyses remain to be done.
Compared to Past Research
The WashU BMJ cohort study is the largest and most comprehensive human evidence in this area, but it did not emerge from a vacuum. A 2024 retrospective cohort study found that semaglutide was associated with reduced incidence and relapse of cannabis use disorder specifically in real-world populations outside the veteran system, which adds some generalizability to the current findings. Animal model work has consistently shown that GLP-1 agonism reduces self-administration of alcohol, cocaine, nicotine, and opioids in rodent models, establishing the biological plausibility that the human data now extends.
Earlier human observational studies found associations between GLP-1 use and reduced alcohol-related hospitalizations. A 2025 molecular study documented crossover between GLP-1 receptor pathways and endocannabinoid system signaling in reward-relevant brain regions, providing a mechanistic framework for the cannabis-specific signal in the current paper. The consistency across prior preclinical and small human studies, combined with the scale of the current work, represents a genuine accumulation of convergent evidence. That said, prior comparison studies were not independently reviewed for this Lens Card, and full meta-analytic synthesis of the available human literature has not been conducted as of the publication of this study.
Practical Considerations
GLP-1 medications are not small interventions. They require injection or oral dosing, carry a meaningful side effect profile including nausea, gastrointestinal discomfort, and rare but serious risks, and cost several hundred to several thousand dollars monthly without insurance coverage. They are currently approved for diabetes and obesity, not for substance use disorder. Prescribing them off-label for addiction would be premature and, in most insurance contexts, unfeasible.
For patients who are already taking GLP-1 drugs for legitimate metabolic indications, the practical implication is awareness. If a patient is also managing cannabis use and notices a change in their relationship with cannabis after starting semaglutide, that change is biologically plausible and worth discussing with their physician. If a patient with cannabis use disorder is also a candidate for GLP-1 therapy for obesity or diabetes, the addiction-related findings provide one additional argument, not a primary one, for considering that therapy. Monitoring both metabolic and substance use outcomes in these patients is warranted. The practical limiting factors are access, cost, injection burden, and the absence of FDA-approved indication for addiction treatment.
Future Directions (Expected)
The most important next step is the randomized controlled trial. Several are already in development. At least one trial is evaluating semaglutide specifically for alcohol use disorder in veterans. Another is examining GLP-1 receptor agonists for opioid use disorder in outpatient treatment settings. A cocaine use disorder trial is also registered. These prospective, controlled designs will be able to determine causation rather than association, and to evaluate dose, duration, and patient selection with far greater precision than this cohort study allows.
Beyond trials, several questions deserve attention: Which GLP-1 formulation produces the strongest addiction-related signal? Do oral GLP-1 agents replicate the injectable findings? Do effects differ by substance type, severity of use, or concurrent psychiatric diagnosis? Does the endocannabinoid system modulate the GLP-1 effect in people who use cannabis regularly, potentially through CB1 receptor downregulation or ECS tone changes? And importantly, do the mortality reductions hold in non-veteran populations with less care integration? The answers to these questions will determine whether GLP-1 agents move from an interesting observational signal to a genuine therapeutic tool for addiction medicine. That transition, if it comes, would be one of the more consequential developments in addiction pharmacology in a generation.
Misreadings & Bad-Faith Takes
Distortion: “Ozempic cures addiction” or “GLP-1 drugs can treat cannabis use disorder.” This is a distortion. The study shows an association, not causation, and no trial has tested GLP-1 drugs specifically for cannabis use disorder treatment. Corrected read: GLP-1 use was associated with a lower risk of developing cannabis use disorder in a population being treated for diabetes. That is a meaningful signal, not a treatment recommendation.
Distortion: “If you’re addicted, just get an Ozempic prescription.” This is harmful misinformation. GLP-1 medications have significant side effects, require medical supervision, are not approved for addiction, and are inaccessible to many patients due to cost. Treatment for substance use disorder requires comprehensive, individualized care.
Distortion: “This study proves cannabis is addictive and dangerous, and now even GLP-1 drugs can fix it.” Cannabis use disorder, like all substance use disorders, exists on a spectrum. This study does not make a judgment about cannabis. It notes that GLP-1 use was associated with lower diagnostic rates of cannabis use disorder in a veteran population. The nuance matters.
Distortion: “The study is about veterans so it doesn’t apply to anyone else.” The population limitation is real and worth noting, but it does not nullify the finding. It constrains generalizability, it does not eliminate relevance. The biological mechanism, if real, operates across human populations.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Cai M, Choi T, Xie Y, Al-Aly Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026;392:e086886. doi: 10.1136/bmj-2025-086886. PMID: 41781010.
Frequently Asked Questions
What did the BMJ study on GLP-1 drugs and substance use disorders actually find?
The study followed 606,434 U.S. veterans with type 2 diabetes and found that those taking GLP-1 receptor agonists, the class of drugs that includes semaglutide, were 14% less likely to develop any substance use disorder compared to those taking SGLT2 inhibitors, another diabetes medication. The risk reduction was seen across all substances tested: 18% lower for alcohol, 14% for cannabis, 20% for cocaine, 20% for nicotine, and 25% for opioids. Among veterans who already had a substance use disorder, GLP-1 users experienced 40% fewer overdoses and 50% fewer drug-related deaths over three years. This was an observational cohort study, not a randomized controlled trial, so the findings show associations rather than proven cause and effect.
Does this mean GLP-1 drugs like Ozempic or Wegovy can treat cannabis use disorder?
No, not on the current evidence. GLP-1 medications are approved for type 2 diabetes and obesity, not for substance use disorder treatment. This study found an association between GLP-1 use and lower rates of cannabis use disorder diagnosis, but it was not designed to test these drugs as addiction treatments. The researchers themselves call for randomized controlled trials to determine causation before any clinical recommendation could be made. Using GLP-1 drugs off-label for cannabis use disorder would be getting well ahead of the available evidence, and these medications carry meaningful side effects and significant costs that need to be weighed individually.
Why might GLP-1 drugs reduce cravings across so many different substances?
GLP-1 receptors are present not only in the pancreas and gut but also in brain regions involved in reward and craving, including the nucleus accumbens and ventral tegmental area. These are the same circuits that drive compulsive behavior toward alcohol, opioids, cannabis, cocaine, and nicotine. The working hypothesis is that GLP-1 agonism may dampen the dopaminergic signal that makes substances rewarding, reducing what one researcher called “drug noise,” the persistent craving that pulls people toward addictive substances. Because the mechanism would operate at the level of the craving itself rather than any particular drug’s receptor, it could theoretically affect multiple substances simultaneously. This is biologically plausible but has not yet been confirmed in randomized trials.
How does the endocannabinoid system relate to GLP-1 receptor pathways?
Both the endocannabinoid system and the GLP-1 pathway are active in brain regions that regulate appetite, reward, mood, and metabolic signaling. CB1 receptors and GLP-1 receptors are co-expressed in several overlapping areas, and preclinical research has documented molecular crossover between the two systems. For patients who use cannabis and also take GLP-1 medications, this overlap may produce effects on appetite, tolerance, and mood that neither system produces in isolation. The clinical implications of this interaction are not well characterized in human studies yet, making it an important area for future research and for individualized, informed clinical monitoring.
If I am taking a GLP-1 drug and I use cannabis medicinally, should I expect changes?
Some patients who start GLP-1 medications report changes in how they experience substances they previously used, including reduced desire for alcohol or cannabis. This is consistent with the biological hypothesis about GLP-1 receptors and reward circuitry, but individual experiences vary considerably. If you are taking a GLP-1 drug for metabolic reasons and you notice changes in your cannabis use patterns, tolerance, or motivation to use, that is worth discussing with your prescribing physician. It does not mean you should modify your cannabis regimen on your own. The goal is informed, collaborative care where both systems are monitored together.
What are the main limitations of this study?
Several limitations are worth understanding. First, this was a retrospective observational study using health records, not a randomized controlled trial, so it cannot establish causation. Second, the population was predominantly older male veterans within an integrated VA healthcare system, which limits generalizability to women, younger adults, and people in different care settings. Third, cannabis use disorder is frequently undercoded in electronic health records, which could affect the precision of the cannabis-specific findings. Fourth, the study could not fully control for unmeasured differences between patients who received GLP-1 drugs versus SGLT2 inhibitors. Finally, the study does not tell us which specific GLP-1 formulation, dose, or duration produces the strongest signal for addiction-related outcomes.
Are there clinical trials testing GLP-1 drugs specifically for addiction?
Yes, several randomized controlled trials are now in development or active enrollment. At least one trial is evaluating semaglutide for alcohol use disorder in veterans. Another is examining GLP-1 receptor agonists for opioid use disorder in outpatient treatment settings. A trial specifically for cocaine use disorder is also registered on ClinicalTrials.gov. These prospective trials will be able to test causation, evaluate specific dosing protocols, and identify which patient populations benefit most. Results from these trials will be far more actionable than the observational findings from the BMJ cohort study, and Dr. Caplan will cover their results as they emerge.
Does this study change how clinicians should counsel patients who use both GLP-1 drugs and cannabis?
Not dramatically, based on current evidence, but it does add a layer of biological context worth incorporating into clinical conversations. Clinicians who care for patients taking GLP-1 drugs for metabolic reasons and who also use cannabis should be aware that the two systems interact, that some patients may experience changes in their cannabis use patterns, and that monitoring both domains together is appropriate. It does not justify adding GLP-1 drugs to a cannabis treatment plan, nor does it justify reducing or stopping cannabis use because a patient is on semaglutide. What it justifies is a more integrated, curious clinical approach that treats metabolic and behavioral health as genuinely connected domains.
What is “drug noise” and why does it matter to this study?
“Drug noise” is the phrase used by lead researcher Ziyad Al-Aly, MD, to describe the persistent internal preoccupation with craving that drives addictive behavior across substances. It is analogous to the “food noise” that many patients on semaglutide describe losing, the constant background focus on food that drives overeating in people with obesity. Al-Aly’s interpretation of this study is that GLP-1 medications may quiet drug noise in a substance-nonspecific way, targeting the biological pathway of craving rather than the receptor of any particular drug. If this hypothesis holds in randomized trials, it would represent a fundamentally different approach to addiction medicine: one medication class that operates against the craving itself rather than against one specific substance.
Where can I learn more and how can CED Clinic help me navigate these questions?
CED Clinic offers physician-led, personalized care at the intersection of cannabis medicine and metabolic health. If you are managing a condition that involves cannabis use and metabolic concerns, or if you have questions about how your medications interact with your cannabis regimen, Dr. Caplan’s team can provide individualized guidance grounded in the latest clinical evidence. You can reach out directly at cedclinic.com/contact, explore the metabolic care program at cedclinic.com/metabolic, or book a consultation at CEDclinic.com/book. For questions specifically about this study, use the Ask Dr. Caplan link at benjamincaplan.com/ask-dr-caplan.
